Canadian Online Pharmacy

CDER New June 13, 2014

FDA (U.S. Food and Drug Administration)

What's New on the FDA Drugs Site

June 12, 2014


New and Generic Drug Approvals

June 11, 2014

Drug NameActive IngredientDosage Form/RouteSponsorSubmission Type
Adempas riociguat Tablet;Oral Bayer Hlthcare Supplement
Caverject Impulse alprostadil Injectable;Injection Pharmacia and Upjohn Labeling Revision
Colgate Total sodium fluoride; triclosan Paste;Dental Colgate Palmolive Labeling Revision
Doxazosin doxazosin mesylate Tablet;Oral Accord Hlthcare Inc Approval
Duloxetine duloxetine hydrochloride Capsule, Delayed Release;Oral Apotex Inc Approval
Duloxetine Hydrochloride duloxetine hydrochloride Capsule, Delayed Rel Pellets;Oral Breckenridge Pharm Approval
Erlotinib Hydrochloride erlotinib hydrochloride Tablet; Oral Mylan Pharma Approval
Gadavist gadobutrol Solution;Intravenous Bayer Hlthcare Efficacy Supplement with Clinical Data to Support
Magnevist gadopentetate dimeglumine Injectable;Injection Bayer Hlthcare Labeling Revision
Magnevist gadopentetate dimeglumine Injectable;Injection Bayer Hlthcare Labeling Revision
Nicorette nicotine polacrilex Gum, Chewing;Buccal Glaxosmithkline Labeling Revision
Nicorette nicotine polacrilex Gum, Chewing;Buccal Glaxosmithkline Labeling Revision
Nicorette (Mint) nicotine polacrilex Gum, Chewing;Buccal Glaxosmithkline Labeling Revision
Nicorette (Mint) nicotine polacrilex Gum, Chewing;Buccal Glaxosmithkline Labeling Revision
Noxafil posaconazole Tablet, Delayed Release;Oral Merck Sharp Dohme Labeling Revision
Prandimet metformin hydrochloride; repaglinide Tablet;Oral Novo Nordisk Inc Manufacturing Change or Addition
Sutent sunitinib malate Capsule;Oral Cppi Cv Labeling Revision

 


This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery